Drugs / ACC017
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06278389 | Jan → Apr 2024 | — | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07711223 | Nov 2025 → Aug 2028 expected | HIV infectious disease | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07711210 | Mar 2025 → Jun 2027 expected | HIV infectious disease | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06719310 | Aug 2024 → Aug 2025 overdue | HIV infectious disease | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACC017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07711210 ↗ |
| Action | Inhibit | “ACC017 is an integrase inhibitor that will be evaluated for the treatment of HIV infection.” NCT06719310 ↗ |
| Route | Oral | “Participants will receive a single oral dose of ACC017 tablets or placebo under fasting conditions.” NCT06278389 ↗ |